Skip to content
Screener

Ultragenyx Pharmaceutical RARE Gross margin

Discontinued — last reported Q2 '19

Gross margin at other companies

Eli Lilly logo
Eli LillyLLY
83.4%+0.8pp
Amgen logo
AmgenAMGN
69.5%+5.0pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
98.2%-0.7pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
95.5%+23.5pp
Regenxbio logo
RegenxbioRGNX
59.7%+1.0pp
Moderna logo
ModernaMRNA
23.4%-29.1pp

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio1.7×-0.7×

Where this comes from

Calculated from Ultragenyx Pharmaceutical’s reported figures.

gross profit/total revenue=97.2%

Based on trailing twelve months.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed July 30, 2020. Open the filing →

Filed
Jul 31, 2020, 11:29 AM EDT
Fiscal quarter
Q2 FY2020
Calendar quarter
Q2 2020
Accession
0001564590-20-035082

FAQ

What does gross margin mean?
Gross profit (revenue minus cost of revenue) as a percentage of revenue, on a trailing-twelve-month basis. Measures how much of each sales dollar survives the direct cost of producing the goods or services sold.